Direct Compression of Lithothamnion-Derived Calcium Carbonate in Tablet Manufacturing

Raw algae calcium carbonate harvested from the calcareous red algae Lithothamnion calcareum exhibits a porous, irregular particle architecture that lowers bulk density to 0.5 g/cm³ to 0.9 g/cm³ when measured by USP <616> and raises the Hausner ratio above 1.30 in powder flow characterization per USP <1174> unless the API is densified by dry granulation. Direct compression of undensified powder on a production rotary press fitted with B-tooling frequently produces mass variation beyond ±5% because the open-pored particles interlock and rat-hole in the feed frame. A processable direct-compression or granulate-based formulation therefore contains 35% w/w to 45% w/w roller-compacted algae calcium, 45% w/w to 55% w/w microcrystalline cellulose, 2% w/w croscarmellose sodium, and 0.5% w/w to 1.0% w/w magnesium stearate. Roller compaction is run to ribbon density 1.4 g/cm³ to 1.7 g/cm³; below this range the granulate is excessively friable, while above it the downstream tablet press cannot generate sufficient intergranular bonding and capping increases. The terminal compressed tablet core is tested for disintegration in 0.1 N hydrochloric acid at 37 °C per USP <701>, with a limit of 30 min, and for dissolution per USP <711>. Assay of the API is performed by complexometric titration after acid digestion under the compendial Calcium Carbonate monograph, and elemental impurity control follows ICH Q3D with analytical verification by USP <232> and USP <233>.

Tablet press instrumentation on the same B-tooling rotary line shows that ejection force rises sharply when magnesium stearate is below 0.25% w/w, because the abrasive mineral surface drags on the die wall; above 1.0% w/w the hydrophobic lubricant film retards wetting in 0.1 N HCl and slows the carbonate reaction. Lubricated blending is therefore limited to 5 min at 25 rpm in a V-blender after the magnesium stearate is added, and over-lubrication is monitored by the dissolution curve rather than by hardness alone. Capping risk increases when tablet hardness exceeds 120 N because porous algae calcium particles recover elastically after compression. Precompression force is held at 8 kN to 12 kN, and main compression is adjusted to produce crushing strengths of 80 N to 100 N measured by USP <1217>. A 625 mg core formulated with 40% w/w calcium in the raw carbonate yields 250 mg elemental calcium per tablet, and automatic weight checks at 5 min intervals are used to detect segregation caused by particle density differences between the algae calcium and the cellulosic filler.

Hard capsule filling on an intermittent-motion machine with dosator nozzles depends on densified granulate because the dosator pin compresses a fixed volume of powder at a constant stroke depth. Tapped density of 0.85 g/cm³ to 1.10 g/cm³ and a Hausner ratio below 1.35 per USP <1174> are required to keep fill weight relative standard deviation below 2.5%. The filled blend typically contains 55% w/w wet-granulated algae calcium, 38% w/w mannitol or xylitol, 2% w/w crospovidone, and 1% w/w sodium stearyl fumarate. Wet granulation uses purified water or an aqueous povidone K30 binder at 3% w/w solids; the wet mass is dried in a fluid-bed dryer to moisture below 1.5% w/w by Karl Fischer titration per USP <921> Method Ic. Terminal hard gelatin or hypromellose capsules are tested for uniformity of dosage units per USP <905> and disintegration per USP <701>. Because algae calcium retains residual organic mineralized matrix, dissolution in 0.1 N hydrochloric acid may be slower than precipitated calcium carbonate; published data for this specific configuration is limited, so dissolution profiles must be generated with the actual granule particle size distribution, capsule shell lot, and dissolution apparatus conditions recorded.

When Effervescent Granule Matrices Require Acid Buffering Without Viscosity Collapse

Effervescent granulation of algae calcium carbonate uses the carbonate lattice as both active calcium source and carbon dioxide donor. For citric acid monohydrate as the acid source, the stoichiometric requirement is 2 mol hydrogen ions for every 1 mol calcium carbonate. Because citric acid monohydrate is triprotic and has a molecular mass of 210 g/mol, the theoretical acid load is 140 g citric acid monohydrate per 100 g calcium carbonate. The ratio shifts upward when tartaric acid is included to reduce hygroscopicity and to accelerate reconstitution. Processing must exclude free moisture because the acid-carbonate reaction proceeds rapidly at water activity above 0.6; wet granulation is replaced by anhydrous dry blending or by alcohol granulation in a jacketed high-shear mixer. Granulation with anhydrous ethanol at 8% w/w to 12% w/w liquid addition produces a workable mass without initiating effervescence. The granulate is dried at 35 °C to 45 °C under vacuum to residual ethanol below 0.5% and filled into aluminum-laminate sachets. Terminal effervescent granules are reconstituted in 150 mL to 200 mL water; a clear solution is expected within 90 s to 120 s. The product is tested for water content by USP <921>, sachet uniformity by USP <905>, and microbial limits by USP <61> and USP <62>. Storage above 25 °C or above 40% relative humidity accelerates premature acid-carbonate reaction and carbon dioxide loss, so barrier sachets are required.

When direct dry blending is selected instead of alcohol granulation, segregation risk is high because citric acid monohydrate and calcium carbonate differ in bulk density by more than 0.3 g/cm³. Low-shear tumble mixing at 60% to 70% of nominal blender volume with sampling at 10 locations after 10 min is used to confirm blend uniformity. A single-dose sachet containing 1000 mg calcium carbonate and 1400 mg citric acid monohydrate follows the stoichiometric acid ratio, but many effervescent calcium formulae increase the acid load by 5% w/w to 10% w/w to ensure complete reaction and a transparent solution after stirring. The processing suite must maintain relative humidity below 30% during dry blending and sachet filling.

Oral suspension development depends on controlling sedimentation and pH buffering rather than dissolution, because algae calcium carbonate remains practically insoluble at neutral pH and only releases calcium ions after gastric pH falls below 5.0. The API is first wet-milled or high-pressure homogenized to a D90 particle size of 10 µm to 25 µm; smaller particles increase surface area but may generate carbonate-mediated pH drift above 8.0 in the vehicle. A stable suspension vehicle is built with xanthan gum at 0.25% w/w, microcrystalline cellulose and carboxymethylcellulose sodium at 1.5% w/w, and glycerin at 10% w/w as a humectant. Xanthan gum above 0.5% w/w creates a yield stress that impedes pouring from a measuring cup and is therefore avoided. Preservative selection excludes benzoic acid when the pH exceeds 7.0 because antimicrobial activity declines; potassium sorbate at 0.1% w/w is used with a citrate buffer to hold the pH at 7.0. Terminal oral suspension at 50 mg/mL calcium carbonate equivalent is tested for uniformity of dosage units per USP <905> and for particle size stability under accelerated storage conditions. Dissolution testing in neutral media is not appropriate for this dosage form because the drug substance is intentionally suspended rather than solubilized; the critical quality attribute is resuspendability after 10 manual inversions of the bottle.

What Calcium Salt Derivatization Route Is Compatible With Injectable Pharmacopoeial Monographs?

Algae calcium carbonate in native particulate form is not a direct injectable API. Direct parenteral dispersion fails USP <788> particulate matter limits and produces an alkaline pH shift that is incompatible with intravenous infusion. Injectable use requires chemical conversion into a pharmacopoeially recognized soluble calcium salt. The carbonate feedstock is first dissolved in 1 M hydrochloric acid at a 2:1 HCl-to-CaCO3 molar ratio, yielding calcium chloride in solution and releasing carbon dioxide. After clarification through 0.45 µm and 0.22 µm filters, the calcium chloride solution is either isolated as calcium chloride dihydrate or neutralized with purified gluconic acid at a 2:1 gluconic acid-to-calcium carbonate molar ratio to obtain calcium gluconate. The resulting calcium gluconate must meet the Calcium Gluconate Injection monograph and the general requirements of USP <1>, USP <85>, USP <788>, and ICH Q3D elemental impurity limits. Endotoxin control is performed before terminal heat sterilization because marine-sourced algae calcium raw material can carry bioburden. Published data for this specific derivatization configuration is limited; each batch must demonstrate complete absence of residual carbonate after acid digestion, because residual particles would reappear as particulate matter after sterilization. The terminal injectable product is a clear solution of calcium gluconate or calcium chloride with an elemental calcium concentration normally specified between 0.1 mEq/mL and 0.2 mEq/mL, depending on the registered formulation.

Parenteral dosage development requires a closed processing line from the point of clarified salt solution onward, because microbiological control of a marine-sourced feedstock cannot rely on terminal filtration alone. The calcium salt solution is warmed to 70 °C to 80 °C before membrane filtration to reduce viscosity and improve flux through polyethersulfone filters. Terminal moist-heat sterilization is carried out at 121 °C for 15 min for thermostable ampoules or vials; calcium gluconate solutions may require sterilization at 115 °C for 30 min to avoid caramelization. The solution is sparged with nitrogen before sealing to prevent calcium carbonate reformation from dissolved carbon dioxide at high pH. Residual carbonate is quantified by acid displacement manometry or by ion chromatography with suppressed conductivity detection. Process parameters must be qualified on a batch-specific basis using pilot-scale data before sustained production, and direct addition of algae calcium powder to a parenteral vehicle is never permitted.

Coated Tablet and Film-Coat Barrier Design for Disintegration Compliance

Aqueous film coating of algae calcium tablets is performed with a polyvinyl alcohol-based ready-to-use coating system at 2.5% w/w to 3.5% w/w weight gain. The coating suspension is prepared at 15% w/w solids and sprayed in a perforated pan coater with inlet air temperature 60 °C to 80 °C, product temperature 38 °C to 45 °C, and spray rate adjusted to maintain coating-chamber relative humidity below 50%. The barrier reduces surface dusting and improves swallowability without functioning as an enteric coat. Enteric coating of calcium carbonate is generally contraindicated because the carbonate lattice requires a pH below 4.5 for protonation and carbon dioxide release; an enteric polymer such as methacrylic acid-ethyl acrylate copolymer delays dissolution until the small intestine and reduces gastric calcium ion release. Coated tablets are tested for disintegration in 0.1 N hydrochloric acid at 37 °C per USP <701> and for dissolution per USP <711>. The film-coated terminal dosage form contains 300 mg to 600 mg calcium carbonate equivalent per tablet, adjusted after assay of the sourced algae calcium because organic components can lower calcium carbonate content by 2% w/w to 5% w/w relative to mineral-grade precipitated calcium carbonate.